drugset / Trial / NCT02885259
HyQvia in Multifocal Motor Neuropathy
NaSingle-groupOpen-labelTreatment
Summary
Subcutaneous immunoglobulin (SCIG) and recombinant human hyaluronidase (rHuPH20) will be tested in patient witch MMN and currently under maintenance treatment with IVIG for safety, tolerability and efficacy.
Timeline
- Start
- 2016-09
- Primary completion
- 2017-12
- Completion
- 2018-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human immunoglobulin | Protein / enzyme biologic | — | Subcutaneous |
| Subject | rHuPH20 | Protein / enzyme biologic | — | Subcutaneous |